Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421

Relapse is a major obstacle in the cure of acute myeloid leukemia (AML). The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS). Patients were randomized to receive standard-dose DAT (daunorubicin, cytarabine, and thio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Becton, David, Dahl, Gary V., Ravindranath, Yaddanapudi, Chang, Myron N., Behm, Fred G., Raimondi, Susana C., Head, David R., Stine, Kimo C., Lacayo, Norman J., Sikic, Branimir Ivan, Arceci, Robert J., Weinstein, Howard
Natura: Artigo
Lingua:Inglês
Pubblicazione: © 2006 by The American Society of Hematology 2006
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895393/
https://ncbi.nlm.nih.gov/pubmed/16254147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2004-08-3218
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi